{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:26Z","timestamp":1793061326988,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centre for the Development of Industrial Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016028","name":"Valencia Innovation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102929","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:32:48Z","timestamp":1784730768000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2667-234X","authenticated-orcid":false,"given":"Diego","family":"Piqueras-Losilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garcia-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Huguet-Lachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argimiro","family":"Mayoral-Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Campillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Nufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouli","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"D\u00edaz-Maqueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Barquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchel","family":"Gonzalez-Barriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Martinez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Gracia","family":"de Garnica Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Artero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Llamus\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-5900","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Cerro-Herreros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102929_bib1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.102929_bib2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1001\/jama.1993.03500150072029","article-title":"Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring","volume":"269","author":"Redman","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2026.102929_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","article-title":"Myotonic dystrophy: diagnosis, management and new therapies","volume":"27","author":"Turner","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.xcrm.2026.102929_bib4","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/ene.13062","article-title":"Cognition in myotonic dystrophy type 1: a 5-year follow-up study","volume":"23","author":"Winblad","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.xcrm.2026.102929_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.755392","article-title":"Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1","volume":"13","author":"Liu","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.xcrm.2026.102929_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaneurol.2014.130","article-title":"Abnormal functional brain connectivity and personality traits in myotonic dystrophy type 1","volume":"71","author":"Serra","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2026.102929_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cortex.2017.08.008","article-title":"The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis","volume":"95","author":"Okkersen","year":"2017","journal-title":"Cortex"},{"key":"10.1016\/j.xcrm.2026.102929_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.20800","article-title":"Cerebral involvement in myotonic dystrophies","volume":"36","author":"Meola","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2026.102929_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification","volume":"172","author":"De Antonio","year":"2016","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.xcrm.2026.102929_bib10","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.3390\/ijms20133365","article-title":"Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy","volume":"20","author":"Sznajder","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102929_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12964-025-02102-5","article-title":"Functions of the Muscleblind-like protein family and their role in disease","volume":"23","author":"Zhou","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.xcrm.2026.102929_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003043","article-title":"Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus","volume":"8","author":"Huguet","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib13","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/hmg\/10.23.2717","article-title":"Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities","volume":"10","author":"Seznec","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib14","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1371\/journal.pgen.0030052","article-title":"CTG trinucleotide repeat \u201cbig jumps\u201d: large expansions, small mice","volume":"3","author":"Gomes-Pereira","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/brain\/aws367","article-title":"Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour","volume":"136","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.xcrm.2026.102929_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1250276","article-title":"Nucleic acid-based therapeutics for the treatment of central nervous system disorders","volume":"14","author":"McCartan","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib19","first-page":"194","article-title":"Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00210-021-02196-x","article-title":"Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review","volume":"395","author":"Moradi","year":"2022","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.xcrm.2026.102929_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4429","article-title":"Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection","volume":"6","author":"Ma","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102929_bib23","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ymthe.2023.05.006","article-title":"Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington\u2019s disease","volume":"31","author":"O\u2019Reilly","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102929_bib25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102929_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib27","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2026.102929_bib28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102929_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Pascual-Gilabert","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2026.102929_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.drudis.2018.08.004","article-title":"RNA-mediated therapies in myotonic dystrophy","volume":"23","author":"Overby","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2026.102929_bib31","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1093\/hmg\/dds306","article-title":"Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise","volume":"21","author":"Chamberlain","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib32","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102929_bib33","article-title":"Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102929_bib34","doi-asserted-by":"crossref","first-page":"eadn6525","DOI":"10.1126\/sciadv.adn6525","article-title":"AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action","volume":"10","author":"Cerro-Herreros","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102929_bib35","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","article-title":"miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models","volume":"9","author":"Cerro-Herreros","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102929_bib36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.omtn.2020.07.021","article-title":"Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy","volume":"21","author":"Cerro-Herreros","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.102929_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.09.001","article-title":"Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression","volume":"34","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.102929_bib38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajhg.2026.01.016","article-title":"Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1","volume":"113","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2026","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.102929_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.molmed.2011.05.004","article-title":"Myotonic dystrophy mouse models: towards rational therapy development","volume":"17","author":"Gomes-Pereira","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib41","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/hmg\/ddw042","article-title":"A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle","volume":"25","author":"Gudde","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib42","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1084\/jem.20171406","article-title":"Alzheimer\u2019s disease: A matter of blood-brain barrier dysfunction?","volume":"214","author":"Montagne","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","article-title":"Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy","volume":"143","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.xcrm.2026.102929_bib44","doi-asserted-by":"crossref","first-page":"9.58.1","DOI":"10.1002\/cpns.25","article-title":"Fluorescein isothiocyanate (FITC)-Dextran Extravasation as a Measure of Blood-Brain Barrier Permeability","volume":"79","author":"Natarajan","year":"2017","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.xcrm.2026.102929_bib45","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1038\/s41467-022-31594-9","article-title":"Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes","volume":"13","author":"Dinc\u00e3","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102929_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.neuron.2012.05.029","article-title":"Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy","volume":"75","author":"Charizanis","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.xcrm.2026.102929_bib47","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/hmg\/ddx115","article-title":"Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy","volume":"26","author":"Wang","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102929_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033218","article-title":"Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain","volume":"7","author":"Suenaga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102929_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41434-022-00316-7","article-title":"Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1","volume":"29","author":"Ait Benichou","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib50","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","article-title":"AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1","volume":"48","author":"Stepniak-Konieczna","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1","volume":"355","author":"Pandey","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cts.12275","article-title":"Sodium Channel Inhibitors Reduce DMPK mRNA and Protein","volume":"8","author":"Witherspoon","year":"2015","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.xcrm.2026.102929_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00155-19","article-title":"Correction of Glycogen Synthase Kinase 3\u03b2 in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice","volume":"39","author":"Wang","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102929_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.662035","article-title":"Integrative Cell Type-Specific Multi-Omics Approaches Reveal Impaired Programs of Glial Cell Differentiation in Mouse Culture Models of DM1","volume":"15","author":"Gonz\u00e1lez-Barriga","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.xcrm.2026.102929_bib55","unstructured":"Regulations.gov 2024 https:\/\/www.regulations.gov\/document\/FDA-2024-D-4624-0002."},{"key":"10.1016\/j.xcrm.2026.102929_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2021.105053","article-title":"Opportunities and challenges of fatty acid conjugated therapeutics","volume":"236","author":"Bhat","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.xcrm.2026.102929_bib57","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib58","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1093\/nar\/gkaa164","article-title":"Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice","volume":"48","author":"Chappell","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/acschembio.0c00847","article-title":"Sixteen Different Types of Lipid-Conjugated siRNAs Containing Saturated and Unsaturated Fatty Acids and Exhibiting Enhanced RNAi Potency","volume":"16","author":"Kubo","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xcrm.2026.102929_bib60","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jnc.14000","volume":"141","author":"Murphy","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102929_bib61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13241","article-title":"Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid","volume":"509","author":"Nguyen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102929_bib62","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1021\/acs.molpharmaceut.5b00580","article-title":"Fatty Acid-Binding Protein 5 Facilitates the Blood\u2013Brain Barrier Transport of Docosahexaenoic Acid","volume":"12","author":"Pan","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xcrm.2026.102929_bib63","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/jnc.13943","article-title":"The blood-brain barrier fatty acid transport protein 1 (FATP1\/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport","volume":"141","author":"Ochiai","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102929_bib64","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s11095-024-03743-w","article-title":"Iron Reduces the Trafficking of Fatty Acids from Human Immortalised Brain Microvascular Endothelial Cells Through Modulation of Fatty Acid Transport Protein 1 (FATP1\/SLC27A1)","volume":"41","author":"Supti","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.plefa.2017.04.004","article-title":"Fatty Acid Transporting Proteins: Roles in Brain Development, Aging, and Stroke","volume":"136","author":"Zhang","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.xcrm.2026.102929_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40659-024-00496-z","article-title":"Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models","volume":"57","author":"Moreno","year":"2024","journal-title":"Biol. Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of Antisense Drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.xcrm.2026.102929_bib68","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1089\/hum.2022.069","article-title":"Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1","volume":"33","author":"Ait Benichou","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102929_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93666-y","article-title":"Effective silencing of miR-126 after ischemic stroke by means of intravenous \u03b1-tocopherol\u2013conjugated heteroduplex oligonucleotide in mice","volume":"11","author":"Suzuki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102929_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/nar\/gkn904","article-title":"Potent inhibition of microRNA in vivo without degradation","volume":"37","author":"Davis","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102929_bib71","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81892","article-title":"Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome","volume":"12","author":"Lee","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2026.102929_bib72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/ijms23020592","article-title":"DM1 Transgenic Mice Exhibit Abnormal Neurotransmitter Homeostasis and Synaptic Plasticity in Association with RNA Foci and Mis-Splicing in the Hippocampus","volume":"23","author":"Potier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102929_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/science.adc9020","article-title":"Molecular basis of astrocyte diversity and morphology across the CNS in health and disease","volume":"378","author":"Endo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102929_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7785","article-title":"Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome","volume":"13","author":"Shao","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102929_bib75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.omtn.2023.01.006","article-title":"Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS\/FTD mice","volume":"31","author":"Takeuchi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.102929_bib76","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/ijms22062939","article-title":"Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces \u03b1-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P\u2217A53T\u2217\u03b1-Synuclein Transgenic Mice","volume":"22","author":"Pavia-Collado","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102929_bib77","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2026.102929_bib78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.xcrm.2026.102929_bib79","series-title":"Haschek and Rousseaux\u2019s Handbook of Toxicologic Pathology","first-page":"1","article-title":"Toxicologic Pathology: An Introduction","author":"Haschek","year":"2013"},{"key":"10.1016\/j.xcrm.2026.102929_bib80","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","article-title":"Myotonic Dystrophy in Transgenic Mice Expressing an Expanded CUG Repeat","volume":"289","author":"Mankodi","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102929_bib81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4939-6817-6_22","article-title":"Ultrasensitive Hybridization-Based ELISA Method for the Determination of Phosphorodiamidate Morpholino Oligonucleotides in Biological samples","volume":"1565","author":"Burki","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102929_bib82","series-title":"Antisense RNA Design, Delivery, and Analysis","first-page":"207","article-title":"Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts","author":"Moreno","year":"2022"},{"key":"10.1016\/j.xcrm.2026.102929_bib83","doi-asserted-by":"crossref","first-page":"e0178931","DOI":"10.1371\/journal.pone.0178931","article-title":"In silico discovery of substituted pyrido[2,3-d] pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models","volume":"12","author":"Gonz\u00e1lez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102929_bib84","series-title":"Encyclopedia of Neuroscience","first-page":"573","article-title":"Astrocyte: Identification Methods","author":"Scheller","year":"2009"},{"key":"10.1016\/j.xcrm.2026.102929_bib85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.32607\/20758251-2015-7-2-42-47","article-title":"NeuN As a Neuronal Nuclear Antigen and Neuron Differentiation Marker","volume":"7","author":"Gusel\u2019nikova","year":"2015","journal-title":"Acta Nat."},{"key":"10.1016\/j.xcrm.2026.102929_bib86","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.29.3S-1","article-title":"Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse","volume":"29","author":"Berridge","year":"2016","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.xcrm.2026.102929_bib87","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1177\/0192623312439125","article-title":"Proliferative and Nonproliferative Lesions of the Rat and Mouse Central and Peripheral Nervous Systems","volume":"40","author":"Kaufmann","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.xcrm.2026.102929_bib88","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.29.1S","article-title":"Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse","volume":"29","author":"Nolte","year":"2016","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.xcrm.2026.102929_bib89","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/0192623312438736","article-title":"Proliferative and nonproliferative lesions of the rat and mouse urinary system","volume":"40","author":"Frazier","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.xcrm.2026.102929_bib90","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse","volume":"13","author":"Irwin","year":"1968","journal-title":"Psychopharmacologia"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:26:36Z","timestamp":1793060796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003460"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102929","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}